SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Hann-Chorng Kuo, OnabotulinumtoxinA Treatment for Overactive Bladder in the Elderly: Practical Points and Future Prospects, Drugs & Aging, 2016, 33, 1, 1

    CrossRef

  2. 2
    Yuan-Hong Jiang, Hueih-Ling Ong, Hann-Chorng Kuo, Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome—A real-life practice of 290 cases in a single center, Neurourology and Urodynamics, 2016, 35, 1
  3. 3
    Karen Noblett, Steven Siegel, Jeffrey Mangel, Tomas L. Griebling, Suzette E. Sutherland, Erin T. Bird, Craig Comiter, Daniel Culkin, Jason Bennett, Samuel Zylstra, Fangyu Kan, Kellie Chase Berg, Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder, Neurourology and Urodynamics, 2016, 35, 1
  4. 4
    M. Lacout, A. Guinet-Lacoste, M. Popoff, D. Verollet, F. Lebreton, G. Amarenco, Ancienneté de la neurovessie et efficacité d’une première injection de toxine botulique intradétrusorienne, Progrès en Urologie, 2015, 25, 11, 642

    CrossRef

  5. 5
    Chung-Cheng Wang, Chun-Hou Liao, Hann-Chorng Kuo, Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder, Urological Science, 2015, 26, 1, 7

    CrossRef

  6. 6
    Bilal Farhan, Gamal Ghoniem, Clinical Pathways of Third-Line Treatment of Overactive Bladder in the Elderly, Current Bladder Dysfunction Reports, 2015, 10, 4, 381

    CrossRef

  7. 7
    Yuan-Hong Jiang, Chun-Hou Liao, Hann-Chorng Kuo, Current and potential urological applications of botulinum toxin A, Nature Reviews Urology, 2015, 12, 9, 519

    CrossRef

  8. 8
    Forrest C. Jellison, Evaluation and Treatment of Overactive Bladder after History of Cancer Treatment, Current Bladder Dysfunction Reports, 2015, 10, 1, 31

    CrossRef

  9. 9
    J.M. Mba Angoué, G. Olagui, Y.S. Oliveira, B.K. Manou, J.J. Wyndaele, La cause d’incontinence urinaire chez les blessés médullaires sous sondages intermittents, Journal de Réadaptation Médicale : Pratique et Formation en Médecine Physique et de Réadaptation, 2015,

    CrossRef

  10. 10
    Sachin Malde, Christopher Dowson, Olivia Fraser, Jane Watkins, Muhammed S. Khan, Prokar Dasgupta, Arun Sahai, Patient experience and satisfaction with Onabotulinumtoxin A for refractory overactive bladder, BJU International, 2015, 116, 3
  11. 11
    Maria Paola Bertapelle, Mario Vottero, Giulio Del Popolo, Marco Mencarini, Edoardo Ostardo, Michele Spinelli, Antonella Giannantoni, Anna D’Ausilio, Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System, World Journal of Urology, 2015, 33, 8, 1109

    CrossRef

  12. 12
    Silke Walleser Autiero, Natalie Hallas, Christopher D. Betts, Jeremy L. Ockrim, The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK, BJU International, 2015, 116, 6
  13. 13
    Sheng-Fu Chen, Hann-Chorng Kuo, Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity, Journal of the Formosan Medical Association, 2015, 114, 7, 583

    CrossRef

  14. 14
    Hann-Chorng Kuo, Treatment of overactive bladder: Past, present, and future, Urological Science, 2015, 26, 1, 1

    CrossRef

  15. 15
    Carlos Martins da Silva, Michael B. Chancellor, Christopher Patrick Smith, Francisco Cruz, Use of botulinum toxin for genitourinary conditions: What is the evidence?, Toxicon, 2015, 107, 141

    CrossRef

  16. 16
    Hann-Chorng Kuo, Botulinum Toxin A Injections for Non-neurogenic Overactive Bladder, Current Bladder Dysfunction Reports, 2014, 9, 3, 254

    CrossRef

  17. 17
    Axel Hegele, Sonja Knippschild, Carsten Frohme, Jörg Hänze, Peter Olbert, Rainer Hofmann, Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?, BMC Urology, 2014, 14, 1, 85

    CrossRef

  18. 18
    Mang L. Chen, Christopher J. Chermansky, Bing Shen, James R. Roppolo, William C. de Groat, Changfeng Tai, Electrical Stimulation of Somatic Afferent Nerves in the Foot Increases Bladder Capacity in Healthy Human Subjects, The Journal of Urology, 2014, 191, 4, 1009

    CrossRef

  19. 19
    Katherine Warren, Helena Burden, Paul Abrams, Lower urinary tract symptom, Current Opinion in Urology, 2014, 24, 1, 3

    CrossRef

  20. 20
    Altaf Mangera, Christopher R Chapple, OnabotulinumtoxinA for the treatment of overactive bladder, Clinical Investigation, 2014, 4, 3, 281

    CrossRef

  21. 21
    Lanka Abeywickrama, Angamuthu Arunkalaivanan, Monica Quinlan, Repeated botulinum toxin type A (Dysport®) injections for women with intractable detrusor overactivity: a prospective outcome study, International Urogynecology Journal, 2014, 25, 5, 601

    CrossRef

  22. You have free access to this content22
    Pravisha Ravindra, Benjamin L. Jackson, Richard J. Parkinson, Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox®) or abobotulinumtoxinA (Dysport®) make a difference?, BJU International, 2013, 112, 1
  23. 23
    J. Seth, M. S. Khan, P. Dasgupta, A. Sahai, Botulinum Toxin—What Urologic Uses Does the Data Support?, Current Urology Reports, 2013, 14, 3, 227

    CrossRef

  24. 24
    R. Caremel, J.-N. Cornu, J. Kerdraon, E. Castel-Lacanal, C. Bastide, F. Bruyere, L. Guy, G. Karsenty, Les médicaments de la vessie, Progrès en Urologie, 2013, 23, 15, 1271

    CrossRef

  25. 25
    J. Quentin Clemens, Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB), Yearbook of Urology, 2013, 2013, 50

    CrossRef

  26. 26
    Tina G. Rashid, Jeremy L. Ockrim, Male incontinence, Current Opinion in Urology, 2013, 23, 6, 545

    CrossRef

  27. 27
    Jamie M. Bartley, Emily S. Blum, Larry T. Sirls, Kenneth M. Peters, Understanding Clinic Options for Overactive Bladder, Current Urology Reports, 2013, 14, 6, 541

    CrossRef

  28. 28
    S. Gaillet, P. Bardot, B. Bernuz, R. Boissier, K. Lenne-Aurier, I. Thiry-Escudier, H. Tournebise, E. Lechevallier, G. Karsenty, Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity, Progrès en Urologie, 2012, 22, 17, 1064

    CrossRef

  29. 29
    Antonio Marte, Onabotulinumtoxin A for Treating Overactive/Poor Compliant Bladders in Children and Adolescents with Neurogenic Bladder Secondary to Myelomeningocele, Toxins, 2012, 5, 1, 16

    CrossRef